Patents by Inventor Arne Scholz
Arne Scholz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11701347Abstract: The present invention relates to the use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine (compound A), more particularly (+)5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine (compound A?), for treating diffuse large B-cell lymphoma (DLBCL), especially in germinal-centre B-cell type of diffuse large B-cell lymphoma and especially in diffuse large B-cell lymphoma which cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or an overexpression of MYC and/or BCL2.Type: GrantFiled: February 12, 2019Date of Patent: July 18, 2023Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventor: Arne Scholz
-
Patent number: 11492358Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I) in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: February 26, 2021Date of Patent: November 8, 2022Assignees: The Broad Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Christopher Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick Ryan McCarren
-
Publication number: 20210316017Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an immune checkpoint inhibitor, and component B being a pharmaceutically acceptable salt of the alkaline-earth radio-nuclide radium-223, the combination being useful for the treatment or prophylaxis of cancer.Type: ApplicationFiled: November 24, 2020Publication date: October 14, 2021Applicant: Bayer Pharma AktiengesellschaftInventor: Arne SCHOLZ
-
Patent number: 10981932Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical 2019 compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 17, 2017Date of Patent: April 20, 2021Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
-
Publication number: 20210015806Abstract: The present invention relates to the use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine (compound A), more particularly (+)5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine (compound A?), for treating diffuse large B-cell lymphoma (DLBCL), especially in germinal-centre B-cell type of diffuse large B-cell lymphoma and especially in diffuse large B-cell lymphoma which cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or an overexpression of MYC and/or BCL2.Type: ApplicationFiled: February 12, 2019Publication date: January 21, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventor: Arne SCHOLZ
-
Patent number: 10717749Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: September 26, 2016Date of Patent: July 21, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
-
Publication number: 20200087322Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 17, 2017Publication date: March 19, 2020Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
-
Publication number: 20200030463Abstract: The present invention relates to the use of radium-223, particularly a pharmaceutically acceptable salt of radium-223, and combinations comprising radium-223, for the preparation of a medicament for the treatment or prophylaxis of a haematologic malignancy disease, particularly for the treatment of multiple myeloma thereof.Type: ApplicationFiled: February 20, 2018Publication date: January 30, 2020Inventor: Arne SCHOLZ
-
Patent number: 10214542Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: September 30, 2016Date of Patent: February 26, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Daniel Hog, Jens Geisler, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Gerhard Siemeister, Nicolas Werbeck
-
Patent number: 10124007Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being a pharmaceutically acceptable salt of radium 223. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer with bone metastases.Type: GrantFiled: December 1, 2014Date of Patent: November 13, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ningshu Liu, Arne Scholz, Andrea Hägebarth
-
Publication number: 20180282346Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: September 30, 2016Publication date: October 4, 2018Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich LÜCKING, Daniel HOG, Jens GEISLER, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Gerhard SIEMEISTER, Nicolas WERBECK
-
Publication number: 20180273548Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: ApplicationFiled: September 26, 2016Publication date: September 27, 2018Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich LÜCKING, Jens GEISLER, Daniel HOG, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Kunzeng ZHENG, Ping GAO, Gang CHEN, Jiajun XI, Simon Anthony HERBERT, Gerhard SIEMEISTER, Nicolas WERBECK
-
Publication number: 20180214583Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an immune checkpoint inhibitor, and component B being a pharmaceutically acceptable salt of the alkaline-earth radio nuclide radium-223, the combination being useful for the treatment or prophylaxis of cancer.Type: ApplicationFiled: August 8, 2016Publication date: August 2, 2018Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventor: Arne SCHOLZ
-
Patent number: 9962389Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).Type: GrantFiled: April 14, 2017Date of Patent: May 8, 2018Assignee: Bayer Intellectual Property GmbHInventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
-
Patent number: 9963464Abstract: The present invention relates to novel macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: April 8, 2015Date of Patent: May 8, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Ulrich Lücking, Pierre Wasnaire, Arne Scholz, Philip Lienau, Gerhard Siemeister, Christian Stegmann, Ulf Bömer, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi
-
Publication number: 20180110888Abstract: The present invention relates to combinations comprising compounds A and B, compound A being a 17?-hydroxylase/C17,20-lyase (CYP17) inhibitor, and compound B being a pharmaceutically acceptable salt of the alkaline-earth radionuclide radium-223 and their use for the treatment or prophylaxis of a disease, particurlarly for the treatment of cancer.Type: ApplicationFiled: November 17, 2017Publication date: April 26, 2018Inventor: Arne SCHOLZ
-
Publication number: 20180078560Abstract: The present invention relates to the use of 4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A), more particularly (+)-4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A?), for treating multiple myeloma.Type: ApplicationFiled: March 21, 2016Publication date: March 22, 2018Applicant: Bayer Pharma AktiengesellschaftInventor: Arne SCHOLZ
-
Patent number: 9902716Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). R2 represents the group (a).Type: GrantFiled: October 13, 2015Date of Patent: February 27, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Dirk Kosemund, Ulrich Lücking, Gerhard Siemeister, Arne Scholz, Philip Lienau
-
Publication number: 20180050040Abstract: The present invention relates to 4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A), more particularly (+)-4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A?), for use in treating lymphoma, preferably diffuse large B-cell lymphoma (DLBCL) mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymBurkitt's lymphoma, adult T-cell lymphoma (ATL) and Hodgkin's lymphoma, more preferably DLBCL and ATL.Type: ApplicationFiled: March 21, 2016Publication date: February 22, 2018Inventors: Arne SCHOLZ, Takashi ISHIDA
-
Patent number: 9884849Abstract: The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: October 14, 2015Date of Patent: February 6, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Dirk Kosemund, Ulrich Lücking, Gerhard Siemeister, Arne Scholz, Philip Lienau